Group Members @2026a-keerthana-gunaretnam, @2026a-nourelden-rihan, @2026a-ritika-saha, @2026a-rahul-yaji
Project Goals Bacteriophages represent a promising alternative to antibiotics in addressing the global challenge of AMR, as evidenced by historical and contemporary reviews (Barron, 2022). The MS2 phage, a single-stranded RNA bacteriophage, encodes the lysis protein L, which disrupts the host bacterial cell wall to facilitate phage progeny release (Chamakura et al., 2017a). Engineering L protein aims to optimize phage performance for therapeutic use, including improved stability, production yields (titers), and lytic potency. This review analyzes each goal using insights from mutational studies (Chamakura et al., 2017b), in vitro characterizations (Mezhyrova et al., 2023), engineering approaches (Lin et al., 2023), phage therapy overviews (Barron, 2022), and computational design strategies (King et al., 2025). The analysis ranks goals by difficulty, as specified, and elucidates the meaning of “higher toxicity”